Background: In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die ... invoked for treatment initiation was the presence of bone lesions (n=77), while ...

Medical history included multiple myeloma diagnosed 4 years previously ... The differential diagnosis of pigmented skin lesions includes: benign naevus, dysplastic naevus, seborrhoeic keratosis, ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...

Non-secretory myeloma is a rare form of myeloma. In people with this form, myeloma cells do not release an abnormal protein called paraprotein, making it harder to diagnose than other types of ...

Revlimid (lenalidomide) is a brand-name oral capsule prescribed to treat multiple myeloma and certain other blood cell cancers in adults. This article covers topics such as side effects ...

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...

Early treatment with intravenous bisphosphonates at first radiographic evidence of bone lesions in patients with solid tumors or evidence of osteopenia in patients with multiple myeloma can ...

As detailed previously, patient education is of paramount importance for the appropriate and safe use of lenalidomide. Patients should be counseled in detail about the risks of fetal exposure to ...

This medication is an immunomodulatory agent, prescribed for multiple myeloma, and erythema nodosum leprosum (ENL). It works on the immune system to decrease certain substances that cause skin ...

more than one focal lesion appears on an MRI scan Many people with myeloma show abnormalities in lab blood tests before they develop symptoms. Multiple myeloma requires active treatment if one or ...

Historically, we evaluated myeloma through monoclonal proteins or free light chains in the blood and urine and percentage of plasma cells in the bone marrow. But this is like the iceberg ...